{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T19:40:02Z","timestamp":1730662802628,"version":"3.28.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T00:00:00Z","timestamp":1730592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T00:00:00Z","timestamp":1730592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Scientific Research Project of Hunan Provincial Health Commission","award":["D202304058683"],"award-info":[{"award-number":["D202304058683"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-77971-w","type":"journal-article","created":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T19:01:59Z","timestamp":1730660519000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["MFAP3L predicts tumor microenvironment status, molecular subtypes and clinical benefit in patients with bladder cancer"],"prefix":"10.1038","volume":"14","author":[{"given":"Guoou","family":"Xie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiezheng","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiyan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongcai","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weimin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,3]]},"reference":[{"key":"77971_CR1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41572-023-00475-w","volume":"9","author":"Bladder cancer","year":"2023","unstructured":"Bladder cancer. Nat. Rev. Dis. Primers 9, 59 https:\/\/doi.org\/10.1038\/s41572-023-00475-w (2023).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"77971_CR2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.immuni.2022.12.008","volume":"56","author":"J Park","year":"2023","unstructured":"Park, J., Hsueh, P. C., Li, Z. & Ho, P. C. Microenvironment-driven metabolic adaptations guiding CD8\u2009+\u2009T cell anti-tumor immunity. Immunity. 56, 32\u201342. https:\/\/doi.org\/10.1016\/j.immuni.2022.12.008 (2023).","journal-title":"Immunity"},{"key":"77971_CR3","doi-asserted-by":"publisher","unstructured":"Yu, A. et al. Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8(+) T cell infiltration and functional transition. J. Immunother Cancer. 11 https:\/\/doi.org\/10.1136\/jitc-2023-007230 (2023).","DOI":"10.1136\/jitc-2023-007230"},{"key":"77971_CR4","doi-asserted-by":"publisher","first-page":"0271","DOI":"10.34133\/research.0271","volume":"6","author":"A Yu","year":"2023","unstructured":"Yu, A. et al. Continuous Expression of Interferon Regulatory Factor 4 Sustains CD8(+) T Cell Immunity against Tumor. Res. (Wash D C). 6, 0271. https:\/\/doi.org\/10.34133\/research.0271 (2023).","journal-title":"Res. (Wash D C)"},{"key":"77971_CR5","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1021\/pr800238p","volume":"7","author":"B Kang","year":"2008","unstructured":"Kang, B. et al. Evaluation of hepatic-metastasis risk of colorectal cancer upon the protein signature of PI3K\/AKT pathway. J. Proteome Res. 7, 3507\u20133515. https:\/\/doi.org\/10.1021\/pr800238p (2008).","journal-title":"J. Proteome Res."},{"key":"77971_CR6","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/j.bbadis.2014.04.006","volume":"1842","author":"X Lou","year":"2014","unstructured":"Lou, X. et al. MFAP3L activation promotes colorectal cancer cell invasion and metastasis. Biochim. Biophys. Acta. 1842, 1423\u20131432. https:\/\/doi.org\/10.1016\/j.bbadis.2014.04.006 (2014).","journal-title":"Biochim. Biophys. Acta"},{"key":"77971_CR7","doi-asserted-by":"publisher","unstructured":"de G\u00f3mez, I. et al. Decreased levels of Microfibril-Associated Glycoprotein (MAGP)-1 in patients with colon cancer and obesity are associated with changes in extracellular matrix remodelling. Int. J. Mol. Sci. 22, https:\/\/doi.org\/10.3390\/ijms22168485 (2021).","DOI":"10.3390\/ijms22168485"},{"key":"77971_CR8","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.5754\/hge11380","volume":"58","author":"JH Wu","year":"2011","unstructured":"Wu, J. H., Tian, X. Y. & Hao, C. Y. The significance of a group of molecular markers and clinicopathological factors in identifying colorectal liver metastasis. Hepatogastroenterology. 58, 1182\u20131188. https:\/\/doi.org\/10.5754\/hge11380 (2011).","journal-title":"Hepatogastroenterology"},{"key":"77971_CR9","doi-asserted-by":"publisher","unstructured":"Kujawa, K. A. et al. Microfibril Associated Protein 5 (MFAP5) Is Related to Survival of Ovarian Cancer Patients but Not Useful as a Prognostic Biomarker. Int. J. Mol. Sci. 23 https:\/\/doi.org\/10.3390\/ijms232415994 (2022).","DOI":"10.3390\/ijms232415994"},{"key":"77971_CR10","doi-asserted-by":"publisher","unstructured":"Hu, J. et al. Neoadjuvant immunotherapy, chemotherapy, and combination therapy in muscle-invasive bladder cancer: A multi-center real-world retrospective study. Cell. Rep. Med. 3 https:\/\/doi.org\/10.1016\/j.xcrm.2022.100785 (2022).","DOI":"10.1016\/j.xcrm.2022.100785"},{"key":"77971_CR11","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1093\/jnci\/djx243","volume":"110","author":"Q Mo","year":"2018","unstructured":"Mo, Q. et al. Prognostic power of a tumor differentiation gene signature for bladder urothelial carcinomas. J. Natl. Cancer Inst. 110, 448\u2013459. https:\/\/doi.org\/10.1093\/jnci\/djx243 (2018).","journal-title":"J. Natl. Cancer Inst."},{"key":"77971_CR12","doi-asserted-by":"publisher","unstructured":"Robertson, A. G. et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 171 https:\/\/doi.org\/10.1016\/j.cell.2017.09.007 (2017).","DOI":"10.1016\/j.cell.2017.09.007"},{"key":"77971_CR13","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","volume":"25","author":"W Choi","year":"2014","unstructured":"Choi, W. et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 25, 152\u2013165. https:\/\/doi.org\/10.1016\/j.ccr.2014.01.009 (2014).","journal-title":"Cancer Cell."},{"key":"77971_CR14","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1073\/pnas.1318376111","volume":"111","author":"JS Damrauer","year":"2014","unstructured":"Damrauer, J. S. et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc. Natl. Acad. Sci. U S A. 111, 3110\u20133115. https:\/\/doi.org\/10.1073\/pnas.1318376111 (2014).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"77971_CR15","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-12-0077-T","volume":"18","author":"G Sj\u00f6dahl","year":"2012","unstructured":"Sj\u00f6dahl, G. et al. A molecular taxonomy for urothelial carcinoma. Clin. Cancer Res. 18, 3377\u20133386. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0077-T (2012).","journal-title":"Clin. Cancer Res."},{"key":"77971_CR16","doi-asserted-by":"publisher","first-page":"244ra291","DOI":"10.1126\/scitranslmed.3008970","volume":"6","author":"S Rebouissou","year":"2014","unstructured":"Rebouissou, S. et al. EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Sci. Transl Med. 6, 244ra291. https:\/\/doi.org\/10.1126\/scitranslmed.3008970 (2014).","journal-title":"Sci. Transl Med."},{"key":"77971_CR17","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun, A. et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur. Urol. 77, 420\u2013433. https:\/\/doi.org\/10.1016\/j.eururo.2019.09.006 (2020).","journal-title":"Eur. Urol."},{"key":"77971_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330 (2000).","journal-title":"Nucleic Acids Res."},{"key":"77971_CR19","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/pro.3715","volume":"28","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 28, 1947\u20131951. https:\/\/doi.org\/10.1002\/pro.3715 (2019).","journal-title":"Protein Sci."},{"key":"77971_CR20","doi-asserted-by":"publisher","first-page":"D587","DOI":"10.1093\/nar\/gkac963","volume":"51","author":"M Kanehisa","year":"2023","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M. & Ishiguro-Watanabe, M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 51, D587\u2013D592. https:\/\/doi.org\/10.1093\/nar\/gkac963 (2023).","journal-title":"Nucleic Acids Res."},{"key":"77971_CR21","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P Charoentong","year":"2017","unstructured":"Charoentong, P. et al. Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade. Cell. Rep. 18, 248\u2013262. https:\/\/doi.org\/10.1016\/j.celrep.2016.12.019 (2017).","journal-title":"Cell. Rep."},{"key":"77971_CR22","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers, M. et al. IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930\u20132940. https:\/\/doi.org\/10.1172\/JCI91190 (2017).","journal-title":"J. Clin. Invest."},{"key":"77971_CR23","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1038\/s41591-018-0157-9","volume":"24","author":"N Auslander","year":"2018","unstructured":"Auslander, N. et al. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nat. Med. 24, 1545\u20131549. https:\/\/doi.org\/10.1038\/s41591-018-0157-9 (2018).","journal-title":"Nat. Med."},{"key":"77971_CR24","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.cell.2018.09.035","volume":"175","author":"MF Sanmamed","year":"2018","unstructured":"Sanmamed, M. F. & Chen, L. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell. 175, 313\u2013326. https:\/\/doi.org\/10.1016\/j.cell.2018.09.035 (2018).","journal-title":"Cell"},{"key":"77971_CR25","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.7150\/thno.53649","volume":"11","author":"J Hu","year":"2021","unstructured":"Hu, J. et al. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer. Theranostics. 11, 3089\u20133108. https:\/\/doi.org\/10.7150\/thno.53649 (2021).","journal-title":"Theranostics"},{"key":"77971_CR26","doi-asserted-by":"publisher","unstructured":"Li, H. et al. S100A5 attenuates efficiency of Anti-PD\u2010L1\/PD\u20101 immunotherapy by inhibiting CD8\u2009+\u2009T cell\u2010mediated anti\u2010cancer immunity in bladder carcinoma. Adv. Sci. 10 https:\/\/doi.org\/10.1002\/advs.202300110 (2023).","DOI":"10.1002\/advs.202300110"},{"key":"77971_CR27","doi-asserted-by":"publisher","unstructured":"Cai, Z. et al. BCAT2 Shapes a noninflamed tumor microenvironment and induces resistance to anti-PD\u20101\/PD\u2010L1 immunotherapy by negatively regulating proinflammatory chemokines and anticancer immunity. Adv. Sci. 10 https:\/\/doi.org\/10.1002\/advs.202207155 (2023).","DOI":"10.1002\/advs.202207155"},{"key":"77971_CR28","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","volume":"72","author":"R Seiler","year":"2017","unstructured":"Seiler, R. et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur. Urol. 72, 544\u2013554. https:\/\/doi.org\/10.1016\/j.eururo.2017.03.030 (2017).","journal-title":"Eur. Urol."},{"key":"77971_CR29","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12916-021-01925-6","volume":"19","author":"KH Ho","year":"2021","unstructured":"Ho, K. H. et al. Glycolysis-associated lncRNAs identify a subgroup of cancer patients with poor prognoses and a high-infiltration immune microenvironment. BMC Med. 19, 59. https:\/\/doi.org\/10.1186\/s12916-021-01925-6 (2021).","journal-title":"BMC Med."},{"key":"77971_CR30","doi-asserted-by":"publisher","unstructured":"Zeng, H. et al. Stromal LAG-3\u2009+\u2009cells infiltration defines poor prognosis subtype muscle-invasive bladder cancer with immunoevasive contexture. J. Immunother. Cancer. 8 https:\/\/doi.org\/10.1136\/jitc-2020-000651 (2020).","DOI":"10.1136\/jitc-2020-000651"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77971-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77971-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77971-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T19:02:04Z","timestamp":1730660524000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77971-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,3]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["77971"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-77971-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,3]]},"assertion":[{"value":"28 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26545"}}